InpharmD vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 39)
InpharmD logo

InpharmD

EmergingHealthcare

General

AI drug information platform with clinical pharmacist review for healthcare providers; $6.5M seed from 645 Ventures and YC competing with UpToDate for complex drug interaction and dosing guidance.

AI VisibilityBeta
Overall Score
D39
Category Rank
#398 of 596
AI Consensus
90%
Trend
up
Per Platform
ChatGPT
37
Perplexity
39
Gemini
39

About

InpharmD is an Atlanta-based healthcare technology company providing AI-assisted drug information and clinical pharmacist intelligence to healthcare providers — enabling physicians, nurses, and clinical staff to get evidence-based answers to complex drug questions (drug interactions, off-label use guidance, dosing in special populations, emerging therapies) through an AI platform that combines clinical pharmacist review with database-backed pharmaceutical intelligence. Founded in 2018 and a Y Combinator W21 graduate, InpharmD raised $6.63 million total including a $6.5 million seed round in December 2023 led by 645 Ventures with participation from Qlarant Capital and Atlanta Ventures.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

39
Overall Score
90
#398
Category Rank
#2
90
AI Consensus
83
up
Trend
stable
37
ChatGPT
92
39
Perplexity
93
39
Gemini
89
37
Claude
96
35
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.